The ASRGL1 Knockout SK-OV-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-OV-3 human ovarian adenocarcinoma cell line. Using CRISPR/Cas9-mediated gene disruption, the ASRGL1 locus is targeted to abolish its enzymatic activity. This product offers a loss-of-function model for investigating ASRGL1 (asparaginase-like 1) in cancer biology. The polyclonal format maintains genetic diversity, supporting pooled functional studies, drug screening, and pathway analysis.
SK-OV-3 is a widely used epithelial ovarian cancer cell line from patient ascites, with mutant p53 and inherent chemoresistance. It serves as a key model for ovarian cancer progression, drug resistance, and metastasis. Its p53 deficiency is crucial because p53 transcriptionally activates ASRGL1, enabling investigation of ASRGL1 in a p53-mutant background that reflects clinical tumors.
ASRGL1 encodes a cytoplasmic L-asparaginase that hydrolyzes asparagine to aspartic acid and ammonia, depleting extracellular asparagine and suppressing mTORC1 signaling. Its expression is activated by p53 and nutrient stress via the GCN2-ATF4 pathway. Loss of ASRGL1 leads to mTORC1 hyperactivity, reduced apoptosis, and cell cycle progression. The enzyme functions as a homodimer and interacts with substrates L-asparagine and isoaspartyl peptides, as well as with PIMT for protein repair via its isoaspartyl peptidase activity. Key pathway components include ASNS, GCN2, mTORC1, ATF4, and PIMT.
In SK-OV-3 cells lacking wild-type p53, ASRGL1 dysregulation may promote asparagine addiction and chemoresistance. This polyclonal knockout population enables study of ASRGL1 loss on asparagine metabolism, mTORC1 activity, and stress survival without clonal selection bias. The model is valuable for investigating apoptosis, metabolic vulnerabilities, and tumor progression mechanisms in p53-mutant ovarian cancers.
Researchers can apply this product in Western blotting (ASRGL1, mTOR pathway markers such as phospho-S6K), RT-qPCR (ASRGL1, ATF4, CHOP), asparaginase activity assays, cell viability/proliferation assays, apoptosis detection by Annexin V/PI flow cytometry, metabolomic profiling of asparagine/aspartate, and xenograft tumor models to evaluate therapeutic responses. For further details or to request a quote, please contact Ascent Research.
